Title
Differences in Melanoma Between Canada and New South Wales, Australia: A Population-Based Genes, Environment, and Melanoma (GEM) Study.

Permalink
https://escholarship.org/uc/item/1500t80p

Journal
JID innovations, 1(1)

ISSN
2667-0267

Authors
Yardman-Frank, Joseph Michael
Glassheim, Elyssa
Kricker, Anne
et al.

Publication Date
2021-03-01

DOI
10.1016/j.xjidi.2021.100002

Copyright Information
This work is made available under the terms of a Creative Commons Attribution License, available at https://creativecommons.org/licenses/by/4.0/

Peer reviewed
Differences in Melanoma Between Canada and New South Wales, Australia: A Population-Based Genes, Environment, and Melanoma (GEM) Study

Joseph Michael Yardman-Frank, Elyssa Glassheim, Anne Kricker, Bruce K. Armstrong, Loraine D. Marrett, Li Luo, Anne E. Cust, Klaus J. Busam, Irene Orlow, Richard P. Gallagher, Stephen B. Gruber, Hoda Anton-Culver, Stefano Rosso, Roberto Zanetti, Peter A. Kanetsky, Terence Dwyer, Alison Venn, Julia Lee-Taylor, Colin B. Begg, Nancy E. Thomas and Marianne Berwick

In an effort to understand the difference between melanomas diagnosed in Australia (New South Wales) and Canada, where the incidence in New South Wales is almost three times greater than in Canada, and mortality is twice as high although survival is slightly more favorable, we had one pathologist review 1,271 melanomas from British Columbia and Ontario, Canada, to compare these to melanomas in New South Wales, Australia. We hypothesized that histopathologic characteristics might provide insight into divergent pathways to melanoma development. We found a number of differences in risk factors and tumor characteristics between the two geographic areas. There were higher mole counts and darker phenotypes in the Canadian patients, while the Australian patients had greater solar elastosis, more lentigo maligna melanomas, and more tumor infiltrating lymphocytes. We hypothesize that the differences observed may illustrate different etiologies — the cumulative exposure pathway among Australian patients and the nevus pathway among Canadian patients. This is one of the largest studies investigating the divergent pathway hypothesis and is particularly robust due to the evaluation of all lesions by one dermatopathologist.

INTRODUCTION

Melanoma incidence is greater at latitudes with high levels of ambient UVR (Baade et al., 2012). Canada’s average estimated UVR levels are a little more than half those of New South Wales, Australia, at 16.11 kJ/m²/day in Vancouver, British Columbia (49°N) and 19.11 kJ/m²/day in Toronto, Ontario (44°N) compared with 32.21 kJ/m²/day in Sydney, New South Wales, Australia (34°S) (Lee-Taylor et al., 2010). Melanoma incidence in New South Wales (67.5 per 100,000 males; 42.3, females) is almost three times higher than the estimated incidence in British Columbia (22.3, males; 18.7, females) and Ontario (28.5, males; 20.2, females) (Canadian Cancer Statistics Advisory Committee, 2019; Cancer Institute NSW, 2016). Australian melanoma mortality in the year 2000 (4.4 per 100,000 males; 2.2, females) was twice that in Canada (2.0, males; 1.1, females) (Australian Institute of Health and Welfare, 2012; Canadian Cancer Society’s Advisory Committee on Cancer Statistics, 2013), yet the five-year relative survival was slightly more favorable in Australia (2006–2010) than Canada (2006–2008) in men (88.5% vs. 85%) and women (93.6% vs. 92%).

We hypothesized that, given the substantial difference in UVR and melanoma incidence and the small difference in relative survival between New South Wales and Canada, patient and histopathologic characteristics in melanoma might differ between regions and give some insight into divergent pathways to melanoma development.

MATERIALS AND METHODS

Our study included 1,271 individuals from British Columbia and Ontario, Canada, and New South Wales, Australia, with first primary
### Table 1. Univariate and Multivariable Logistic Regression (N = 1,271)

| Characteristics          | Canada (n = 546) n (%) | NSW (n = 725) n (%) | NSW versus Canada OR (95% CI) Univariate | P-value | NSW versus Canada OR (95% CI) Multivariable | P-value |
|--------------------------|------------------------|---------------------|------------------------------------------|---------|--------------------------------------------|---------|
| **Patient characteristics** |                        |                     |                                          |         |                                            |         |
| Age at diagnosis         |                        |                     |                                          |         |                                            |         |
| <49                      | 198 (36.3)             | 210 (29.0)          | 1 (Referent)                             |         | 1 (Referent)                               |         |
| 50–69                    | 241 (44.1)             | 291 (40.1)          | 1.14 (0.88–1.47)                         | 0.33    | 0.61 (0.43–0.85)                           | 0.00    |
| 70+                      | 107 (19.6)             | 224 (30.9)          | 1.97 (1.46–2.67)                         | <0.001  | 0.88 (0.57–1.34)                           | 0.54    |
| Missing                  | 0                      | 0                   |                                          |         |                                            |         |
| Sex                      |                        |                     |                                          |         |                                            |         |
| Male                     | 269 (49.3)             | 408 (56.3)          | 1.00 (Referent)                          |         | 1.00 (Referent)                            |         |
| Female                   | 277 (50.7)             | 317 (43.7)          | 0.75 (0.60–0.94)                         | 0.01    | 0.64 (0.47–0.88)                           | 0.006   |
| Missing                  | 0                      | 0                   |                                          |         |                                            |         |
| **Phenotypic index**     |                        |                     |                                          |         |                                            |         |
| Dark                     | 162 (29.7)             | 172 (23.7)          | 1.00 (Referent)                          |         | 1.00 (Referent)                            |         |
| Medium                   | 189 (34.6)             | 306 (42.2)          | 1.52 (1.15–2.02)                         | 0.003   | 1.63 (1.15–2.29)                           | 0.005   |
| Fair                     | 151 (27.7)             | 246 (33.9)          | 1.53 (1.14–2.06)                         | 0.004   | 1.46 (1.03–2.09)                           | 0.04    |
| Missing                  | 44 (8.1)               | 1 (0.1)             |                                          |         |                                            |         |
| **Mole count**           |                        |                     |                                          |         |                                            |         |
| 0–4                      | 165 (30.2)             | 314 (43.3)          | 1.00 (Referent)                          |         | 1.00 (Referent)                            |         |
| 5–10                     | 102 (18.7)             | 181 (25.0)          | 0.93 (0.69–1.27)                         | 0.66    | 1.05 (0.72–1.53)                           |         |
| 11–25                    | 127 (23.3)             | 137 (18.9)          | 0.57 (0.42–0.77)                         | <0.001  | 0.65 (0.45–0.94)                           |         |
| >25                      | 145 (26.6)             | 92 (12.7)           | 0.33 (0.24–0.46)                         | <0.001  | 0.38 (0.26–0.57)                           | Ptrend < 0.001 |
| Missing                  | 7 (1.3)                | 1 (0.1)             |                                          |         |                                            |         |
| **Family history of melanoma** |                    |                     |                                          |         |                                            |         |
| Absent                   | 484 (88.6)             | 588 (81.1)          | 1.00 (Referent)                          |         | 1.00 (Referent)                            |         |
| Present                  | 58 (10.6)              | 108 (14.9)          | 1.53 (1.09–2.16)                         | 0.01    | 1.57 (1.04–2.37)                           | 0.03    |
| Missing                  | 4 (0.7)                | 29 (0.4)            |                                          |         |                                            |         |
| **Ancestry**             |                        |                     |                                          |         |                                            |         |
| Other                    | 172 (31.5)             | 202 (27.9)          | 1.00 (Referent)                          |         | 1.00 (Referent)                            |         |
| Northern European        | 367 (67.2)             | 513 (67.1)          | 1.19 (0.93–1.52)                         | 0.16    | 1.12 (0.83–1.51)                           | 0.45    |
| Missing                  | 7 (1.3)                | 10 (1.4)            |                                          |         |                                            |         |
| **Tumor characteristics** |                        |                     |                                          |         |                                            |         |
| **Anatomic site**        |                        |                     |                                          |         |                                            |         |
| Trunk                    | 258 (47.3)             | 310 (42.8)          | 1.00 (Referent)                          |         | 1.00 (Referent)                            |         |
| Head and neck            | 65 (11.9)              | 118 (16.3)          | 1.51 (1.07–2.13)                         | 0.02    | 0.78 (0.47–1.31)                           | 0.35    |
| Arms                     | 100 (18.3)             | 117 (16.9)          | 1.14 (0.84–1.55)                         | 0.40    | 0.82 (0.54–1.26)                           | 0.37    |
| Legs                     | 123 (22.5)             | 160 (22.0)          | 1.08 (0.81–1.44)                         | 0.59    | 1.36 (0.92–2.02)                           | 0.12    |
| Missing                  | 0                      | 0                   |                                          |         |                                            |         |
| **Histologic subtype**   |                        |                     |                                          |         |                                            |         |
| Superficial spreading    | 376 (68.9)             | 485 (66.9)          | 1.00 (Referent)                          |         | 1.00 (Referent)                            |         |
| Nodular                  | 61 (11.2)              | 74 (10.2)           | 0.94 (0.65–1.35)                         | 0.74    | 0.76 (0.45–1.28)                           | 0.30    |
| Lentigo maligna          | 36 (6.6)               | 95 (13.1)           | 2.05 (1.36–1.07)                         | 0.001   | 1.37 (0.77–2.43)                           | 0.29    |
| Other                    | 73 (13.4)              | 71 (9.8)            | 0.75 (0.53–1.07)                         | 0.12    | 1.00 (0.56–1.79)                           | 0.99    |
| Missing                  | 0                      | 0                   |                                          |         |                                            |         |
| **AJCC tumor stage (2018 edition)** |            |                     |                                          |         |                                            |         |
| Stage 1a/1b              | 308 (56.4)             | 460 (63.5)          | 1.00 (Referent)                          |         |                                            |         |
| Stage 2a                 | 94 (17.2)              | 110 (15.2)          | 0.78 (0.57–1.07)                         | 0.12    |                                            |         |
| Stage 2b/3a              | 44 (8.1)               | 69 (9.5)            | 1.05 (0.70–1.57)                         | 0.81    |                                            |         |
| Stage 3b/4a              | 36 (6.6)               | 41 (5.7)            | 0.76 (0.48–1.22)                         | 0.26    |                                            |         |
| Stage 4b                 | 10 (1.8)               | 16 (2.2)            | 1.07 (0.48–2.39)                         | 0.87    |                                            |         |
| Missing                  | 54 (9.9)               | 29 (4.0)            |                                          |         |                                            |         |
| **Breslow thickness**    |                        |                     |                                          |         |                                            |         |
| 0.1–1.00 mm              | 338 (61.9)             | 473 (65.2)          | 1.00 (Referent)                          |         | 1.00 (Referent)                            |         |
| 1.01–2.00 mm             | 124 (22.7)             | 136 (18.8)          | 0.78 (0.59–1.04)                         | 0.09    | 0.82 (0.55–1.23)                           | 0.34    |
| 2.01–4.00 mm             | 54 (9.9)               | 80 (11.0)           | 1.06 (0.73–1.54)                         | 0.76    | 0.99 (0.54–1.79)                           | 0.96    |
| >4.00 mm                 | 26 (4.8)               | 36 (5.0)            | 0.99 (0.59–1.67)                         | 0.97    | 0.78 (0.35–1.74)                           | 0.54    |
| Missing                  | 4 (0.7)                | 0                   |                                          |         |                                            |         |

(continued)
melanomas diagnosed in 2000, all reviewed by one dermatopathologist (LF) who conducted a standardized pathology review according to published criteria. Institutional review boards from all centers provided approval, and all subjects signed informed consent. Breslow thickness, histologic subtype, tumor-infiltrating lymphocytes (TILs), solar elastosis, ulceration, presence of mitoses, regression, and presence of a coexisting nevus were determined from the slide review. Age, sex, phenotypic index, back mole count, family history of melanoma, ancestry, and anatomic site was confirmed at interview. Classification of tumors followed the T-category of the American Joint Committee on Cancer tumor staging system (Gershenwald et al., 2017).

Variables were first compared between Canada and New South Wales using univariate logistic regression. Then, a multivariable logistic regression was modeled that mutually adjusted for all patient and tumor characteristics. Tests were two-sided, and a P-value < 0.05 was considered statistically significant. Data were analyzed using Stata/SE 15.1 (StataCorp LLC, College Station, TX).

RESULTS
The results from the univariate and multivariable logistic regression analyses are presented in Table 1 and demonstrate a number of differences in the risk factors and tumor characteristics in Canada versus New South Wales. Most relevant to our thesis are the generally higher mole counts in Canadian cases and the somewhat darker phenotypes of these cases. Regarding tumor characteristics, the New South Wales cases are characterized by tumors that have markedly greater solar elastosis, a greater presence of lentigo maligna melanoma histology, and, importantly, considerably more evidence of TILs.

DISCUSSION
The divergent pathway theory of melanoma hypothesizes two pathways leading to melanoma development (Holman et al., 1983; Whiteman et al., 1998), one requiring high cumulative (chronic) sun exposure and the other high counts of cutaneous nevi, which are precursors to melanoma. Melanomas attributed to the cumulative sun exposure pathway occur more commonly on the head and neck and are more likely to be lentigo maligna melanoma (Holman et al., 1983; Whiteman et al., 2003). Solar elastosis, a marker of cumulative UVR exposure, is associated with melanomas on the head and neck and lentigo maligna melanoma (Thomas et al., 2010). We found New South Wales melanomas to be associated with the head and neck, lentigo maligna melanoma, TILs, and solar elastosis, with TILs and solar elastosis remaining associated in multivariable analysis. In prior GEM analyses, the presence of TILs has been found to be associated with Breslow thickness, anatomic site, histologic subtype, and age (Thomas et al., 2013). Including those factors, as well as other patient and tumor characteristics, in
the presented model did not diminish the association of TILs with New South Wales melanomas.

The presence of TILs with cutaneous melanoma has consistently been associated with improved overall survival. In the larger GEM study population, death from melanoma is reduced 30% in the presence of nonbrisk TILs and 50% with brisk TILs (Thomas et al., 2013). The biological mechanism drawing TILs to some melanomas is not fully understood. Based on our observed association of New South Wales melanomas with TILs and solar elastosis, we speculate that cumulative sun exposure may be contributing. Melanomas with high UVR have increased numbers of DNA mutations (Pleasance et al., 2010). These mutations may cause more neoantigen formation, attracting TILs. This increase in TILs may contribute to the better relative survival observed in Australia.

Melanomas occurring along the nevus pathway are classically associated with a younger age and high nevus counts and found on unexposed skin such as the trunk (Olsen et al., 2009). Prior studies comparing Australia and England have documented a higher nevus density in Australia (Bataille et al., 2009). In this analysis, melanomas occurring in Canada were associated with higher counts of back nevi.

We hypothesize that the difference in melanoma between Canada and New South Wales identified here may illustrate different etiologies. That is, New South Wales melanomas develop disproportionately by way of the cumulative sun exposure pathway and Canadian melanomas develop disproportionately by the nevus pathway. Alternatively, there may be a similar baseline rate of melanoma development from nevi between the two regions, but additional melanomas develop in New South Wales because of the higher UVR exposure.

Our study is unique as we present one of the very largest studies investigating the divergent pathways of melanoma. One dermatopathologist reviewed all slides, enabling robust histologic analysis. By comparing patient and histopathological features between regions, we provide evidence for each pathway within the same study. These data may offer additional leads to the understanding of melanoma etiology and may help to target and appropriately screen individuals in New South Wales and Canada.

Data availability statement
Data can be requested from Nancy E. Thomas or Marianne Berwick after review by the GEM Steering Committee.

ORCIDs
Joseph Michael Yardman-Frank: https://orcid.org/0000-0002-0073-0834
Elyssa Glassheim: https://orcid.org/0000-0001-5195-5112
Anne Kricker: https://orcid.org/0000-0002-7219-1227
Bruce K. Armstrong: https://orcid.org/0000-0001-8940-7525
Lidia Sacchetto: https://orcid.org/0000-0001-6590-325X

ACKNOWLEDGMENTS
This work was conducted in Albuquerque, New Mexico, USA.
This work was supported by the National Cancer Institute at the National Institutes of Health (Award Number U01CA83180, R01CA112524, R01CA12524-05S2 to MB; R01CA112243, R01CA12243-05S1, K07CA0704139 to NET; P01 CA06980 to MB and NET; R01CA233524 to MB, NET, and HA-C; P30CA14089 to SBG; and P30CA118100 to MB), the National Institute of Environmental Health Sciences at the National Institutes of Health (P30 ES010126 to NET), and the University of Sydney Medical Foundation Program grant (to BKA). AEC received a National Health and Medical Research Council Career Development Fellowship (114784).
GEM Study Group: Coordinating Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA: Marianne Berwick (Principal Investigator [PI], currently at the University of New Mexico, Albuquerque, NM, USA; Colin Begg, PhD (co-PI); Irene Orlow, PhD, MS (co-Investigator); Klaus J. Busam, MD (Dermatopathologist); Pampa Roy, PhD (Senior Dermatologist); Ajay Sharma, MS (Laboratory Technician); Emily La Pillia, MS (Senior Laboratory Technician); Sarah Yoo (Senior Laboratory Technician); and Neel Reiner, MS (Biostatistician). University of New Mexico, Albuquerque, NM, USA: Marianne Berwick, MPH, PhD (PI); Li Luo, PhD (Biostatistician); and Tawny W. Boyce, MPH (Data Manager). Study Centers: The University of Sydney and The Cancer Council New South Wales, Sydney, Australia: Anne E. Cust, PhD (PI); Bruce K. Armstrong, MD, PhD (former PI); and Anne Kricker, PhD (former co-PI). Menzies Institute for Medical Research University of Tasmania, Hobart, Australia: Alison Venn (current PI); Terence Dwyer (PI, currently at University of Oxford, United Kingdom); and Paul Tucker (Dermatopathologist). British Columbia Cancer Research Centre, Vancouver, Canada: Richard P. Gallagher, MA (PI). Cancer Care Ontario, Toronto, Canada: Lorraine D. Marrett, PhD (PI) and Lynn From, MD (Dermatopathologist). CPO, Center for Cancer Prevention, Torino, Italy: Roberta Zanetti, MD (PI); Stefano Rosso, MD, MSc (co-PI); and Lidia Sacchetto, PhD (Biostatistician). University of California, Irvine, CA, USA: Hoda Anton-Culver, PhD (PI). University of Michigan, Ann Arbor, MI, USA: Stephen B. Gruber, MD, MPH, PhD (PI, currently at University of Southern California, Los Angeles, CA, USA); Shu-Chen Huang, MS, MBA (co-Investigator, joint at USC–University of Michigan). University of North Carolina, Chapel Hill, NC, USA: Nancy E. Thomas, MD, PhD (PI); Kathleen Conway, PhD (co-Investigator); David W. Ollila, MD (co-Investigator); Pamela A. Groben, MD (Dermatopathologist); Sharon N. Edmiston, BA (Research Analyst); Honglin Hao (Laboratory Specialist); Eloise Parrish, MSPH (Laboratory Specialist); Jill S. Frank, MS (Research Assistant); David C. Gibbs, BS (Research Assistant, currently MD/PhD candidate at Emory University, Atlanta, GA, USA). University of Pennsylvania, Philadelphia, PA, USA: Timothy R. Rebeck, PhD (former PI) and Peter A. Kanetsky, MPH, PhD (PI, currently at H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA). UV data consultants: Julia Lee-Taylor, PhD, and Sasha Madronich, PhD, National Centre for Atmospheric Research, Boulder, CO, USA.

CONFLICT OF INTEREST
The authors disclose no potential conflicts of interest.

REFERENCES
Australian Institute of Health and Welfare. Cancer survival and prevalence in Australia: period estimates from 1982 to 2010. https://www.aihw.gov.au/reports/cancer/survival-and-prevalence-in-australia-perio/contents/table-of-contents; 2012 (accessed 9 August 2020).
Baade P, Meng X, Youl P. Time trends and latitudinal differences in melanoma thickness distribution in Australia, 1990–2006. Int J Cancer 2012;130:170–8.

Bataille V, Grulich A, Sasieni P, Swerdlow A, Newton Bishop J, McCarthy W, et al. The association between naevi and melanoma in populations with different levels of sun exposure: a joint case-control study of melanoma in the UK and Australia. Br J Cancer 1998;77:505–10.

Canadian Cancer Society’s Advisory Committee on Cancer Statistics. Canadian cancer statistics 2013. https://www.cancer.ca/~/media/cancer.ca/CW/cancer%20information/cancer%2020101/Canadian%20cancer%20statistics/canadian-cancer-statistics-2013-EN.pdf; 2013 (accessed 9 August 2020).

Canadian Cancer Statistics Advisory Committee. Canadian cancer statistics 2019. https://www.cancer.ca/~/media/cancer.ca/CW/cancer%20information/cancer%2020101/Canadian%20cancer%20statistics/Canadian-Cancer-Statistics-2019-EN.pdf?la=en; 2019 (accessed 24 February 2021).

Cancer Institute NSW. Incidence of melanoma. https://www.cancer.nsw.gov.au/cancer-plan/performancedata/incidence-of-melanoma; 2016. (accessed August 4, 2020).

Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2017;67:472–92.

Holman CD, Armstrong BK, Heenan PJ. A theory of the etiology and pathogenesis of human cutaneous malignant melanoma. J Natl Cancer Inst 1983;71:651–6.

Lee-Taylor J, Madronich S, Fischer C, Mayer B. A climatology of UV radiation, 1979–2000, 65S–65N. In: Gao W, Schmoldt DL, Slusser JR, editors. UV radiation in global climate change: measurements, modeling and effects on ecosystems. Berlin, Heidelberg: Springer; 2010. p. 1–20.

Olsen CM, Zens MS, Stukel TA, Sacerdote C, Chang YM, Armstrong BK, et al. Nevus density and melanoma risk in women: a pooled analysis to test the divergent pathway hypothesis. Int J Cancer 2009;124:937–44.

Pleasance ED, Cheetham R, Stephens PJ, McBride DJ, Humphray SJ, Greenman CD, et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 2010;463:191–6.

Thomas NE, Busam KJ, From L, Kricker A, Armstrong BK, Anton-Culver H, et al. Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes environment and melanoma study. J Clin Oncol 2013;31:4252–9.

Thomas NE, Kricker A, From L, Busam K, Millikan RC, Ritchey ME, et al. Associations of cumulative sun exposure and phenotypic characteristics with histologic solar elastosis. Cancer Epidemiol Biomarkers Prev 2010;19:2932–41.

Whiteman DC, Parsons PG, Green AC. p53 expression and risk factors for cutaneous melanoma: a case-control study. Int J Cancer 1998;77:843–8.

Whiteman DC, Watt P, Purdie DM, Hughes MC, Hayward NK, Green AC. Melanocytic nevi, solar keratoses, and divergent pathways to cutaneous melanoma. J Natl Cancer Inst 2003;95:806–12.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/